Literature DB >> 25797516

Overcoming T cell exhaustion in infection and cancer.

Kristen E Pauken1, E John Wherry2.   

Abstract

Inhibitors of the Programmed Cell Death 1: Programmed Cell Death 1 ligand 1 (PD-1:PD-L1) pathway, a central regulator of T cell exhaustion, have been recently shown to be effective for treatment of different cancers. However, clinical responses are mixed, highlighting the need to better understand the mechanisms of action of PD-1:PD-L1, the role of this pathway in immunity to different tumors, and the molecular and cellular effects of PD-1 blockade. Here, we review the molecular regulation of T cell exhaustion, placing recent findings on PD-1 blockade therapies in cancer in the context of the broader understanding of the roles of the PD-1:PD-L1 pathway in T cell exhaustion during chronic infection. We discuss the current understanding of the mechanisms involved in reversing T cell exhaustion, and outline critical areas of focus for future research, both basic and clinical.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  PD-1; PD-L1; T cell exhaustion; cancer; chronic infection; immunotherapy

Mesh:

Substances:

Year:  2015        PMID: 25797516      PMCID: PMC4393798          DOI: 10.1016/j.it.2015.02.008

Source DB:  PubMed          Journal:  Trends Immunol        ISSN: 1471-4906            Impact factor:   16.687


  133 in total

1.  Differentiation and persistence of memory CD8(+) T cells depend on T cell factor 1.

Authors:  Xinyuan Zhou; Shuyang Yu; Dong-Mei Zhao; John T Harty; Vladimir P Badovinac; Hai-Hui Xue
Journal:  Immunity       Date:  2010-08-27       Impact factor: 31.745

2.  Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection.

Authors:  Hyun-Tak Jin; Ana C Anderson; Wendy G Tan; Erin E West; Sang-Jun Ha; Koichi Araki; Gordon J Freeman; Vijay K Kuchroo; Rafi Ahmed
Journal:  Proc Natl Acad Sci U S A       Date:  2010-08-02       Impact factor: 11.205

Review 3.  Shaping the repertoire of tumor-infiltrating effector and regulatory T cells.

Authors:  Peter A Savage; Daniel S Leventhal; Sven Malchow
Journal:  Immunol Rev       Date:  2014-05       Impact factor: 12.988

4.  Programmed death-1 upregulation is correlated with dysfunction of tumor-infiltrating CD8+ T lymphocytes in human non-small cell lung cancer.

Authors:  Yan Zhang; Shengdong Huang; Dejun Gong; Yanghua Qin; Qian Shen
Journal:  Cell Mol Immunol       Date:  2010-05-31       Impact factor: 11.530

5.  Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients.

Authors:  Julien Fourcade; Zhaojun Sun; Mourad Benallaoua; Philippe Guillaume; Immanuel F Luescher; Cindy Sander; John M Kirkwood; Vijay Kuchroo; Hassane M Zarour
Journal:  J Exp Med       Date:  2010-09-06       Impact factor: 14.307

6.  Cutting edge: Prolonged exposure to HIV reinforces a poised epigenetic program for PD-1 expression in virus-specific CD8 T cells.

Authors:  Ben Youngblood; Alessandra Noto; Filippos Porichis; Rama S Akondy; Zaza M Ndhlovu; James W Austin; Rebeka Bordi; Francesco A Procopio; Toshiyuki Miura; Todd M Allen; John Sidney; Alessandro Sette; Bruce D Walker; Rafi Ahmed; Jeremy M Boss; Rafick-Pierre Sékaly; Daniel E Kaufmann
Journal:  J Immunol       Date:  2013-06-14       Impact factor: 5.422

7.  Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.

Authors:  Suzanne L Topalian; Mario Sznol; David F McDermott; Harriet M Kluger; Richard D Carvajal; William H Sharfman; Julie R Brahmer; Donald P Lawrence; Michael B Atkins; John D Powderly; Philip D Leming; Evan J Lipson; Igor Puzanov; David C Smith; Janis M Taube; Jon M Wigginton; Georgia D Kollia; Ashok Gupta; Drew M Pardoll; Jeffrey A Sosman; F Stephen Hodi
Journal:  J Clin Oncol       Date:  2014-03-03       Impact factor: 44.544

8.  Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma.

Authors:  Omid Hamid; Caroline Robert; Adil Daud; F Stephen Hodi; Wen-Jen Hwu; Richard Kefford; Jedd D Wolchok; Peter Hersey; Richard W Joseph; Jeffrey S Weber; Roxana Dronca; Tara C Gangadhar; Amita Patnaik; Hassane Zarour; Anthony M Joshua; Kevin Gergich; Jeroen Elassaiss-Schaap; Alain Algazi; Christine Mateus; Peter Boasberg; Paul C Tumeh; Bartosz Chmielowski; Scot W Ebbinghaus; Xiaoyun Nicole Li; S Peter Kang; Antoni Ribas
Journal:  N Engl J Med       Date:  2013-06-02       Impact factor: 91.245

Review 9.  At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy.

Authors:  Margaret K Callahan; Jedd D Wolchok
Journal:  J Leukoc Biol       Date:  2013-05-10       Impact factor: 4.962

10.  PD-1 identifies the patient-specific CD8⁺ tumor-reactive repertoire infiltrating human tumors.

Authors:  Alena Gros; Paul F Robbins; Xin Yao; Yong F Li; Simon Turcotte; Eric Tran; John R Wunderlich; Arnold Mixon; Shawn Farid; Mark E Dudley; Ken-Ichi Hanada; Jorge R Almeida; Sam Darko; Daniel C Douek; James C Yang; Steven A Rosenberg
Journal:  J Clin Invest       Date:  2014-03-25       Impact factor: 14.808

View more
  392 in total

1.  Chronic Activation of Innate Immunity Correlates With Poor Prognosis in Cancer Patients Treated With Oncolytic Adenovirus.

Authors:  Kristian Taipale; Ilkka Liikanen; Juuso Juhila; Riku Turkki; Siri Tähtinen; Matti Kankainen; Lotta Vassilev; Ari Ristimäki; Anniina Koski; Anna Kanerva; Iulia Diaconu; Vincenzo Cerullo; Markus Vähä-Koskela; Minna Oksanen; Nina Linder; Timo Joensuu; Johan Lundin; Akseli Hemminki
Journal:  Mol Ther       Date:  2015-08-27       Impact factor: 11.454

2.  Partially exhausted tumor-infiltrating lymphocytes predict response to combination immunotherapy.

Authors:  Kimberly Loo; Katy K Tsai; Kelly Mahuron; Jacqueline Liu; Mariela L Pauli; Priscila M Sandoval; Adi Nosrati; James Lee; Lawrence Chen; Jimmy Hwang; Lauren S Levine; Matthew F Krummel; Alain P Algazi; Miguel Pampaloni; Michael D Alvarado; Michael D Rosenblum; Adil I Daud
Journal:  JCI Insight       Date:  2017-07-20

Review 3.  Mechanisms of Immune Tolerance in Leukemia and Lymphoma.

Authors:  Emily K Curran; James Godfrey; Justin Kline
Journal:  Trends Immunol       Date:  2017-05-13       Impact factor: 16.687

Review 4.  Metabolic reprogramming and apoptosis sensitivity: Defining the contours of a T cell response.

Authors:  Kelsey Voss; Sasha E Larsen; Andrew L Snow
Journal:  Cancer Lett       Date:  2017-09-01       Impact factor: 8.679

5.  N-acetyl cysteine protects anti-melanoma cytotoxic T cells from exhaustion induced by rapid expansion via the downmodulation of Foxo1 in an Akt-dependent manner.

Authors:  Matthew J Scheffel; Gina Scurti; Megan M Wyatt; Elizabeth Garrett-Mayer; Chrystal M Paulos; Michael I Nishimura; Christina Voelkel-Johnson
Journal:  Cancer Immunol Immunother       Date:  2018-02-02       Impact factor: 6.968

Review 6.  Adverse Events Following Cancer Immunotherapy: Obstacles and Opportunities.

Authors:  Kristen E Pauken; Michael Dougan; Noel R Rose; Andrew H Lichtman; Arlene H Sharpe
Journal:  Trends Immunol       Date:  2019-04-30       Impact factor: 16.687

Review 7.  T-cell exhaustion: understanding the interface of chronic viral and autoinflammatory diseases.

Authors:  Eoin F McKinney; Kenneth Gc Smith
Journal:  Immunol Cell Biol       Date:  2016-11       Impact factor: 5.126

8.  Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma.

Authors:  Adil I Daud; Kimberly Loo; Mariela L Pauli; Robert Sanchez-Rodriguez; Priscila Munoz Sandoval; Keyon Taravati; Katy Tsai; Adi Nosrati; Lorenzo Nardo; Michael D Alvarado; Alain P Algazi; Miguel H Pampaloni; Iryna V Lobach; Jimmy Hwang; Robert H Pierce; Iris K Gratz; Matthew F Krummel; Michael D Rosenblum
Journal:  J Clin Invest       Date:  2016-08-15       Impact factor: 14.808

9.  Hepatic Stellate Cell-Macrophage Crosstalk in Liver Fibrosis and Carcinogenesis.

Authors:  Michitaka Matsuda; Ekihiro Seki
Journal:  Semin Liver Dis       Date:  2020-04-02       Impact factor: 6.115

Review 10.  Targeting mitochondria in cancer: current concepts and immunotherapy approaches.

Authors:  Sergey Pustylnikov; Francesca Costabile; Silvia Beghi; Andrea Facciabene
Journal:  Transl Res       Date:  2018-07-31       Impact factor: 7.012

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.